

10/608,907

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal600txm

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAPLUS' AT 16:04:58 ON 20 MAY 2007  
FILE 'CAPLUS' ENTERED AT 16:04:58 ON 20 MAY 2007  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	65.59	238.35
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.36	-9.36

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	65.59	238.35
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.36	-9.36

FILE 'CAPLUS' ENTERED AT 16:05:06 ON 20 MAY 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 May 2007 VOL 146 ISS 22  
FILE LAST UPDATED: 18 May 2007 (20070518/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s us 20070087960/pn  
L5 2 US 20070087960/PN  
(US2007087960/PN)

=> sel rn  
E1 THROUGH E88 ASSIGNED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.64	240.99
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-9.36

FILE 'REGISTRY' ENTERED AT 16:05:45 ON 20 MAY 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

McIntosh

10/608,907

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 MAY 2007 HIGHEST RN 935394-90-4  
DICTIONARY FILE UPDATES: 18 MAY 2007 HIGHEST RN 935394-90-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> s el-e88

1 13734-41-3/BI  
    (13734-41-3/RN)  
1 20724-73-6/BI  
    (20724-73-6/RN)  
1 327614-69-7/BI  
    (327614-69-7/RN)  
1 33985-40-9/BI  
    (33985-40-9/RN)  
1 4099-85-8/BI  
    (4099-85-8/RN)  
1 50-69-1/BI  
    (50-69-1/RN)  
1 503543-43-9/BI  
    (503543-43-9/RN)  
1 503543-44-0/BI  
    (503543-44-0/RN)  
1 55797-67-6/BI  
    (55797-67-6/RN)  
1 108-24-7/BI  
    (108-24-7/RN)  
1 125911-76-4/BI  
    (125911-76-4/RN)  
1 125911-78-6/BI  
    (125911-78-6/RN)  
1 149885-80-3/BI  
    (149885-80-3/RN)  
1 150993-73-0/BI  
    (150993-73-0/RN)  
1 152540-75-5/BI  
    (152540-75-5/RN)  
1 152540-76-6/BI  
    (152540-76-6/RN)  
1 153186-26-6/BI  
    (153186-26-6/RN)  
1 153186-32-4/BI  
    (153186-32-4/RN)  
1 15397-12-3/BI  
    (15397-12-3/RN)  
1 17397-89-6/BI  
    (17397-89-6/RN)  
1 185610-53-1/BI  
    (185610-53-1/RN)  
1 188413-99-2/BI  
    (188413-99-2/RN)  
1 205171-05-7/BI  
    (205171-05-7/RN)  
1 2096-10-8/BI  
    (2096-10-8/RN)  
1 243664-63-3/BI  
    (243664-63-3/RN)  
1 25322-68-3/BI

(25322-68-3/RN)  
1 30361-17-2/BI  
(30361-17-2/RN)  
1 30361-19-4/BI  
(30361-19-4/RN)  
1 31448-54-1/BI  
(31448-54-1/RN)  
1 327614-68-6/BI  
(327614-68-6/RN)  
1 327614-72-2/BI  
(327614-72-2/RN)  
1 36791-04-5/BI  
(36791-04-5/RN)  
1 37353-41-6/BI  
(37353-41-6/RN)  
1 374750-28-4/BI  
(374750-28-4/RN)  
1 374750-30-8/BI  
(374750-30-8/RN)  
1 374750-32-0/BI  
(374750-32-0/RN)  
1 386213-38-3/BI  
(386213-38-3/RN)  
1 40615-36-9/BI  
(40615-36-9/RN)  
1 433935-36-5/BI  
(433935-36-5/RN)  
1 443642-29-3/BI  
(443642-29-3/RN)  
1 472960-22-8/BI  
(472960-22-8/RN)  
1 492-30-8/BI  
(492-30-8/RN)  
1 503543-45-1/BI  
(503543-45-1/RN)  
1 503543-46-2/BI  
(503543-46-2/RN)  
1 503543-47-3/BI  
(503543-47-3/RN)  
1 503543-48-4/BI  
(503543-48-4/RN)  
1 503543-49-5/BI  
(503543-49-5/RN)  
1 503543-50-8/BI  
(503543-50-8/RN)  
1 503543-51-9/BI  
(503543-51-9/RN)  
1 503543-52-0/BI  
(503543-52-0/RN)  
1 503543-55-3/BI  
(503543-55-3/RN)  
1 503806-04-0/BI  
(503806-04-0/RN)  
1 504-78-9/BI  
(504-78-9/RN)  
1 565450-78-4/BI  
(565450-78-4/RN)  
1 57-48-7/BI  
(57-48-7/RN)  
1 58-96-8/BI  
(58-96-8/RN)  
1 622381-09-3/BI  
(622381-09-3/RN)  
1 640281-90-9/BI  
(640281-90-9/RN)  
1 640281-91-0/BI  
(640281-91-0/RN)  
1 640725-69-5/BI  
(640725-69-5/RN)  
1 640725-70-8/BI  
(640725-70-8/RN)  
1 640725-71-9/BI  
(640725-71-9/RN)  
1 640725-72-0/BI  
(640725-72-0/RN)

10/608,907

1 640725-73-1/BI  
(640725-73-1/RN)  
1 640725-74-2/BI  
(640725-74-2/RN)  
1 640725-75-3/BI  
(640725-75-3/RN)  
1 640725-76-4/BI  
(640725-76-4/RN)  
1 640725-77-5/BI  
(640725-77-5/RN)  
1 645004-11-1/BI  
(645004-11-1/RN)  
1 645004-12-2/BI  
(645004-12-2/RN)  
1 645004-13-3/BI  
(645004-13-3/RN)  
1 645004-14-4/BI  
(645004-14-4/RN)  
1 645004-15-5/BI  
(645004-15-5/RN)  
1 645004-16-6/BI  
(645004-16-6/RN)  
1 65-46-3/BI  
(65-46-3/RN)  
1 65-71-4/BI  
(65-71-4/RN)  
1 66-22-8/BI  
(66-22-8/RN)  
1 67-99-2/BI  
(67-99-2/RN)  
1 71-30-7/BI  
(71-30-7/RN)  
1 7392-74-7/BI  
(7392-74-7/RN)  
1 77-76-9/BI  
(77-76-9/RN)  
1 84-11-7/BI  
(84-11-7/RN)  
1 9012-90-2/BI  
(9012-90-2/RN)  
1 9026-28-2/BI  
(9026-28-2/RN)  
1 93-98-1/BI  
(93-98-1/RN)  
1 951-77-9/BI  
(951-77-9/RN)  
1 98-88-4/BI  
(98-88-4/RN)  
1 98530-12-2/BI  
(98530-12-2/RN)

L6

88 (13734-41-3/BI OR 20724-73-6/BI OR 327614-69-7/BI OR 33985-40-9/  
BI OR 4099-85-8/BI OR 50-69-1/BI OR 503543-43-9/BI OR 503543-44-  
0/BI OR 55797-67-6/BI OR 108-24-7/BI OR 125911-76-4/BI OR 125911-  
78-6/BI OR 149885-80-3/BI OR 150993-73-0/BI OR 152540-75-5/BI OR  
152540-76-6/BI OR 153186-26-6/BI OR 153186-32-4/BI OR 15397-12-3/  
BI OR 17397-89-6/BI OR 185610-53-1/BI OR 188413-99-2/BI OR 205171  
-05-7/BI OR 2096-10-8/BI OR 243664-63-3/BI OR 25322-68-3/BI OR  
30361-17-2/BI OR 30361-19-4/BI OR 31448-54-1/BI OR 327614-68-6/BI  
OR 327614-72-2/BI OR 36791-04-5/BI OR 37353-41-6/BI OR 374750-28  
-4/BI OR 374750-30-8/BI OR 374750-32-0/BI OR 386213-38-3/BI OR  
40615-36-9/BI OR 433935-36-5/BI OR 443642-29-3/BI OR 472960-22-8/  
BI OR 492-30-8/BI OR 503543-45-1/BI OR 503543-46-2/BI OR 503543-4  
7-3/BI OR 503543-48-4/BI OR 503543-49-5/BI OR 503543-50-8/BI OR  
503543-51-9/BI OR 503543-52-0/BI OR 503543-55-3/BI OR 503806-04-0  
/BI OR 504-78-9/BI OR 565450-78-4/BI OR 57-48-7/BI OR 58-96-8/BI  
OR 622381-09-3/BI OR

=> file caplus  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
0.45	241.44

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  
CA SUBSCRIBER PRICE

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-9.36

McIntosh

10/608,907

FILE 'CAPLUS' ENTERED AT 16:06:09 ON 20 MAY 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 May 2007 VOL 146 ISS 22  
FILE LAST UPDATED: 18 May 2007 (20070518/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 16

L7 236284 L6

=> s 15 and 17

L8 2 L5 AND L7

=> d bib abs hitstr 1-2 18

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:20697 CAPLUS

DN 140:87662

TI 2'- and 3'-nucleoside prodrugs for treating Flaviviridae infections  
IN Sommadossi, Jean-pierre; La Colla, Paolo; Storer, Richard; Gosselin, Gilles

PA Idenix (Cayman) Limited, Cayman I.; Centre National de la Recherche Scientifique; Universita Degli Studi di Cagliari

SO PCT Int. Appl., 2498 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004003000	A2	20040108	WO 2003-IB3901	20030627
	WO 2004003000	A3	20041104		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2490200	A1	20040108	CA 2003-2490200	20030627
	AU 2003263412	A1	20040119	AU 2003-263412	20030627
	EP 1525209	A2	20050427	EP 2003-761749	20030627
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	CN 1678621	A	20051005	CN 2003-820690	20030627
	JP 2005537242	T	20051208	JP 2004-517162	20030627
	CN 1761677	A	20060419	CN 2003-820501	20030627
	US 2007087960	A1	20070419	US 2003-608907	20030627 <--
	WO 2005020884	A2	20050310	WO 2004-US15395	20040514
	WO 2005020884	A3	20060622		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,			

McIntosh

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

EP 1656093 A2 20060517 EP 2004-776022 20040514  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR  
 US 2007027065 A1 20070201 US 2004-5468 20041206  
 US 2007027104 A1 20070201 US 2004-5469 20041206  
 US 2007027066 A1 20070201 US 2004-5470 20041206  
 US 2007032449 A1 20070208 US 2004-5441 20041206  
 US 2007032407 A1 20070208 US 2004-5473 20041206  
 US 7192936 B2 20070320  
 US 2007037735 A1 20070215 US 2004-5442 20041206  
 US 2007042939 A1 20070222 US 2004-5445 20041206  
 US 2007042991 A1 20070222 US 2004-5447 20041206  
 US 2007042940 A1 20070222 US 2004-5467 20041206  
 US 2007042990 A1 20070222 US 2004-5471 20041206  
 US 2007060503 A1 20070315 US 2004-5440 20041206  
 US 2007060498 A1 20070315 US 2004-5444 20041206  
 US 2007060504 A1 20070315 US 2004-5446 20041206  
 US 2007060541 A1 20070315 US 2004-5466 20041206  
 US 2007060505 A1 20070315 US 2004-5472 20041206  
 NO 2005000466 A 20050323 NO 2005-466 20050127  
 IN 2005DN00341 A 20070202 IN 2005-DN341 20050128  
 PRAI US 2002-392350P P 20020628  
 US 2002-392351P P 20020628  
 US 2003-466194P P 20030428  
 US 2003-470949P P 20030514  
 US 2003-608907 A1 20030627  
 US 2003-609298 A1 20030627  
 WO 2003-IB3901 W 20030627  
 WO 2004-US15395 W 20040514

OS MARPAT 140:87662

AB 2' And 3'-Prodrugs of 1'-, 2'-, 3'-, or 4'-branched  $\beta$ -D or  $\beta$ -L  
 nucleosides, or their pharmaceutically acceptable salts and derivs., are  
 described which are useful in the prevention and treatment of Flaviviridae  
 infections and other related conditions. These modified nucleosides  
 provide superior results against flaviviruses and pestiviruses, including  
 hepatitis C virus and viruses generally that replicate through an  
 RNA-dependent RNA reverse transcriptase. Compds., compns., methods and  
 uses are provided for the treatment of Flaviviridae infection, including  
 HCV infection, that include the administration of an effective amount of the  
 prodrugs of the invention, or their pharmaceutically acceptable salts or  
 derivs. These drugs may optionally be administered in combination or  
 alternation with further antiviral agents to prevent or treat Flaviviridae  
 infections and other related conditions. Preparation of compds. of the  
 invention is included.

IT 9026-28-2

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (NS5B; nucleoside prodrugs for treating Flaviviridae infections)

RN 9026-28-2 CAPLUS

CN Nucleotidyltransferase, ribonucleate, RNA-dependent (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*


IT 33985-40-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (de prodrugs for treating Flaviviridae infections)

RN 33985-40-9 CAPLUS

CN  $\beta$ -D-ribo-Pentodialdo-1,4-furanoside, methyl 2,3-O-(1-  
 methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



McIntosh

10/608,907

IT 37353-41-6, Cysteine protease 149885-80-3, NS3 protease  
433935-36-5, Polymerase  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors; nucleoside prodrugs for treating Flaviviridae infections,  
and use with other agents)  
RN 37353-41-6 CAPLUS  
CN Proteinase, cysteine (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 149885-80-3 CAPLUS  
CN Proteinase, polyprotein-processing, NS3 (CA INDEX NAME)


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 433935-36-5 CAPLUS  
CN Nucleotidyltransferase, polynucleotide (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*


IT 20724-73-6P  
RL: ADV (Adverse effect, including toxicity); BSU (Biological study,  
unclassified); DMA (Drug mechanism of action); PAC (Pharmacological  
activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); RACT (Reactant or reagent); USES (Uses)  
(nucleoside prodrugs for treating Flaviviridae infections)  
RN 20724-73-6 CAPLUS  
CN Cytidine, 2'-C-methyl- (CA INDEX NAME)

Absolute stereochemistry.



IT 125911-78-6 243664-63-3, DNA polymerase  $\beta$   
386213-38-3  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(nucleoside prodrugs for treating Flaviviridae infections)  
RN 125911-78-6 CAPLUS  
CN 5'-Uridylic acid, 2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 243664-63-3 CAPLUS  
CN Nucleotidyltransferase, thymine cyclobutane dimer-bypass deoxyribonucleate  
(CA INDEX NAME)


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 386213-38-3 CAPLUS  
CN 5'-Cytidylic acid, 2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


McIntosh

10/608,907




IT 125911-76-4 150993-73-0 640725-72-0  
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);  
BIOL (Biological study)  
(nucleoside prodrugs for treating Flaviviridae infections)  
RN 125911-76-4 CAPLUS  
CN Uridine 5'-(tetrahydrogen triphosphate), 2'-C-methyl- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.




RN 150993-73-0 CAPLUS  
CN Uridine 5'-(tri-hydrogen diphosphate), 2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 640725-72-0 CAPLUS  
CN Cytidine 5'-(tri-hydrogen diphosphate), 2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 374750-28-4  
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);  
PKT (Pharmacokinetics); BIOL (Biological study)  
(nucleoside prodrugs for treating Flaviviridae infections)  
RN 374750-28-4 CAPLUS  
CN Cytidine 5'-(tetrahydrogen triphosphate), 2'-C-methyl- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.

McIntosh




10/608,907



IT 640725-71-9P  
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(nucleoside prodrugs for treating Flaviviridae infections)  
RN 640725-71-9 CAPLUS  
CN L-Valine, 3'-ester with 2'-C-methylcytidine, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



● 2 HCl

IT 2096-10-8 15397-12-3 31448-54-1  
188413-99-2 374750-30-8 640725-73-1  
640725-74-2 640725-75-3 640725-76-4  
640725-77-5  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(nucleoside prodrugs for treating Flaviviridae infections)  
RN 2096-10-8 CAPLUS  
CN Adenosine, 2-amino- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 15397-12-3 CAPLUS  
CN Adenosine, 2'-C-methyl- (CA INDEX NAME)


Absolute stereochemistry.

10/608,907




RN 31448-54-1 CAPLUS  
CN Uridine, 2'-C-methyl- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 188413-99-2 CAPLUS  
CN Cytidine, 2'-C-ethynyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 374750-30-8 CAPLUS  
CN Guanosine, 2'-C-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 640725-73-1 CAPLUS  
CN Adenosine, 2-amino-2'-C-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/608,907




RN 640725-74-2 CAPLUS  
CN 9H-Purin-2-amine, 6-chloro-9-(2-C-methyl- $\beta$ -D-ribofuranosyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 640725-75-3 CAPLUS  
CN L-Valine, 3',5'-diester with 6-chloro-9-(2-C-methyl- $\beta$ -D-ribofuranosyl)-9H-purin-2-amine, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 640725-76-4 CAPLUS  
CN Adenosine, 2'-C-ethynyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/608,907

RN 640725-77-5 CAPLUS

CN Adenosine, 2-amino-N-cyclopropyl-2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 50-69-1, D-Ribose 57-48-7, D-Fructose, reactions  
65-71-4, Thymine 66-22-8, Uracil, reactions  
71-30-7, Cytosine 77-76-9, 2,2-Dimethoxypropane  
98-88-4, Benzoyl chloride 108-24-7, Acetic anhydride  
13734-41-3 40615-36-9 185610-53-1

RL: RCT (Reactant); RACT (Reactant or reagent)  
(nucleoside prodrugs for treating Flaviviridae infections)

RN 50-69-1 CAPLUS

CN D-Ribose (CA INDEX NAME)


Absolute stereochemistry.



RN 57-48-7 CAPLUS


CN D-Fructose (CA INDEX NAME)

Absolute stereochemistry.




RN 65-71-4 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 5-methyl- (CA INDEX NAME)



RN 66-22-8 CAPLUS


CN 2,4(1H,3H)-Pyrimidinedione (CA INDEX NAME)




McIntosh

10/608,907


RN 71-30-7 CAPLUS  
CN 2(1H)-Pyrimidinone, 6-amino- (CA INDEX NAME)



RN 77-76-9 CAPLUS  
CN Propane, 2,2-dimethoxy- (CA INDEX NAME)



RN 98-88-4 CAPLUS  
CN Benzoyl chloride (CA INDEX NAME)




RN 108-24-7 CAPLUS  
CN Acetic acid, 1,1'-anhydride (CA INDEX NAME)


Ac-O-Ac

RN 13734-41-3 CAPLUS  
CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 40615-36-9 CAPLUS  
CN Benzene, 1,1'-(chlorophenylmethylene)bis[4-methoxy- (CA INDEX NAME)



RN 185610-53-1 CAPLUS  
CN Carbamic acid, diphenyl-, 2-[(2-methyl-1-oxopropyl)amino]-1H-purin-6-yl ester (9CI) (CA INDEX NAME)


McIntosh

10/608,907




IT 492-30-8P 4099-85-8P 7392-74-7P  
30361-17-2P 30361-19-4P 55797-67-6P  
152540-75-5P 327614-69-7P 327614-72-2P  
503543-43-9P 503543-44-0P 503543-45-1P  
503543-46-2P 503543-47-3P 503543-49-5P  
503543-50-8P 503543-51-9P 503543-55-3P  
503806-04-0P 640725-69-5P 640725-70-8P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(nucleoside prodrugs for treating Flaviviridae infections)  
RN 492-30-8 CAPLUS  
CN D-Ribonic acid, 2-C-methyl-,  $\gamma$ -lactone (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 4099-85-8 CAPLUS  
CN  $\beta$ -D-Ribofuranoside, methyl 2,3-O-(1-methylethylidene)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7392-74-7 CAPLUS  
CN D-Ribonic acid, 2-C-methyl-,  $\gamma$ -lactone, 2,3,5-tribenzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 30361-17-2 CAPLUS  
CN D-Ribofuranose, 2-C-methyl-, 2,3,5-tribenzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/608,907



RN 30361-19-4 CAPLUS

CN D-Ribofuranose, 2-C-methyl-, tetrabenzoate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 55797-67-6 CAPLUS

CN  $\beta$ -D-erythro-Pentofuranoside, methyl 4-C-(hydroxymethyl)-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152540-75-5 CAPLUS

CN Uridine, 5-methyl-4'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 327614-69-7 CAPLUS

CN  $\alpha$ -L-Lyxofuranoside, methyl 4-C-[(benzoyloxy)methyl]-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

McIntosh

10/608,907


Absolute stereochemistry.



RN 327614-72-2 CAPLUS

CN  $\alpha$ -L-Lyxofuranoside, methyl 4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 503543-43-9 CAPLUS

CN  $\beta$ -D-Ribofuranoside, methyl 4-C-methyl-2,3-O-(1-methylethylidene)-benzoate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 503543-44-0 CAPLUS

CN D-Ribofuranose, 4-C-methyl-, 1,2,3-triacetate 5-benzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 503543-45-1 CAPLUS


CN Uridine, 4'-C-methyl-, 2',3'-diacetate 5'-benzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh




10/608,907




RN 503543-46-2 CAPLUS  
CN Uridine, 4'-C-methyl-4-thio-, 2',3'-diacetate 5'-benzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 503543-47-3 CAPLUS  
CN Uridine, 4'-C-methyl-4-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 503543-49-5 CAPLUS  
CN Uridine, 5-methyl-4'-C-methyl-, 2',3'-diacetate 5'-benzoate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 503543-50-8 CAPLUS  
CN Uridine, 5-methyl-4'-C-methyl-, 2',3',5'-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/608,907



RN 503543-51-9 CAPLUS

CN Uridine, 5-methyl-4'-C-methyl-4-thio-, 2',3',5'-triacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 503543-55-3 CAPLUS

CN Adenosine, 4'-C-methyl-, 2',3'-diacetate 5'-benzoate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 503806-04-0 CAPLUS

CN Guanosine, 4'-C-methyl-N-(2-methyl-1-oxopropyl)-, 2',3'-diacetate 5'-benzoate 6-(diphenylcarbamate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 640725-69-5 CAPLUS

CN Cytidine, 2'-C-methyl-, 2',3',5'-tribenzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.


McIntosh

10/608,907




RN 640725-70-8 CAPLUS  
CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-, 3'-ester with  
2'-C-methylcytidine (CA INDEX NAME)

Absolute stereochemistry.




IT 152540-76-6P 153186-26-6P 153186-32-4P  
503543-48-4P 503543-52-0P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(nucleoside prodrugs for treating Flaviviridae infections)  
RN 152540-76-6 CAPLUS  
CN Adenosine, 4'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153186-26-6 CAPLUS  
CN Uridine, 4'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 153186-32-4 CAPLUS

McIntosh

10/608,907

CN Guanosine, 4'-C-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 503543-48-4 CAPLUS

CN Cytidine, 4'-C-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 503543-52-0 CAPLUS

CN Cytidine, 5-methyl-4'-C-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 58-96-8, Uridine 65-46-3, Cytidine 951-77-9,  
Deoxycytidine


RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(nucleoside prodrugs for treating Flaviviridae infections, and use with  
other agents)

RN 58-96-8 CAPLUS

CN Uridine (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

10/608,907




RN 65-46-3 CAPLUS  
CN Cytidine (CA INDEX NAME)

Absolute stereochemistry.




RN 951-77-9 CAPLUS  
CN Cytidine, 2'-deoxy- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 67-99-2, Gliotoxin 84-11-7D, Phenanthrenequinone, derivs. 93-98-1D, Benzanilide, derivs. 504-78-9D, Thiazolidine, derivs. 17397-89-6, Cerulenin 25322-68-3D, Polyethylene glycol, conjugates with interferon  $\alpha$ 2a 36791-04-5, Ribavirin 98530-12-2, IntronA 205171-05-7 374750-32-0 443642-29-3 472960-22-8, Albuferon 565450-78-4 622381-09-3  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(nucleoside prodrugs for treating Flaviviridae infections, and use with other agents)  
RN 67-99-2 CAPLUS  
CN 10H-3,10a-Epidithiopyrazino[1,2-a]indole-1,4-dione, 2,3,5a,6-tetrahydro-6-hydroxy-3-(hydroxymethyl)-2-methyl-, (3R,5aS,6S,10aR)- (CA INDEX NAME)


Absolute stereochemistry.




RN 84-11-7 CAPLUS  
CN 9,10-Phenanthrenedione (CA INDEX NAME)

McIntosh

10/608,907



RN 93-98-1 CAPLUS  
CN Benzamide, N-phenyl- (CA INDEX NAME)




RN 504-78-9 CAPLUS  
CN Thiazolidine (CA INDEX NAME)




RN 17397-89-6 CAPLUS  
CN 2-Oxiranecarboxamide, 3-[(4E,7E)-1-oxo-4,7-nonadien-1-yl]-, (2R,3S)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 25322-68-3 CAPLUS  
CN Poly(oxy-1,2-ethanediyl),  $\alpha$ -hydro- $\omega$ -hydroxy- (CA INDEX NAME)



RN 36791-04-5 CAPLUS  
CN 1H-1,2,4-Triazole-3-carboxamide, 1- $\beta$ -D-ribofuranosyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 98530-12-2 CAPLUS  
CN Interferon  $\alpha$ 2 (human leukocyte clone pM21 protein moiety reduced) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*


RN 205171-05-7 CAPLUS

McIntosh

10/608,907


CN 9H-Purine, 6-chloro-9-(2-C-methyl- $\beta$ -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 374750-32-0 CAPLUS  
CN Inosine, 2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 443642-29-3 CAPLUS  
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl- $\beta$ -D-ribofuranosyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 472960-22-8 CAPLUS  
CN Serum albumin (human) fusion protein with interferon  $\alpha$ 2 (human) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 565450-78-4 CAPLUS  
CN Inosine, 2'-C-methyl-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/608,907



RN 622381-09-3 CAPLUS  
CN Cytidine, N-cyclopropyl-2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 645004-11-1 645004-12-2 645004-13-3  
645004-14-4 645004-15-5 645004-16-6  
RL: PRP (Properties)  
(unclaimed sequence; 2'- and 3'-nucleoside prodrugs for treating  
Flaviviridae infections)  
RN 645004-11-1 CAPLUS  
CN RNA, (C-A-U-A-U-G-C-U-C-U-U-A-A-U-C-U-U-U-C-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
RN 645004-12-2 CAPLUS  
CN RNA, (C-A-U-A-U-G-G-U-C-U-U-A-A-U-C-U-U-U-C-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
RN 645004-13-3 CAPLUS  
CN RNA, (C-A-U-A-U-G-C-U-G-U-U-A-A-U-C-U-U-U-C-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
RN 645004-14-4 CAPLUS  
CN RNA, (C-A-U-A-U-C-G-U-C-U-U-A-A-U-C-U-U-U-C-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
RN 645004-15-5 CAPLUS  
CN RNA, (C-A-U-A-U-C-C-U-G-U-U-A-A-U-C-U-U-U-C-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
RN 645004-16-6 CAPLUS  
CN RNA, (C-A-U-A-U-C-C-U-C-U-U-A-A-U-G-U-U-U-C-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
IT 9012-90-2  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
( $\alpha$  and  $\gamma$ ; nucleoside prodrugs for treating Flaviviridae  
infections)  
RN 9012-90-2 CAPLUS  
CN Nucleotidyltransferase, deoxyribonucleate (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2004:20696 CAPLUS  
DN 140:77365  
TI Preparation of modified 2'- and 3'-nucleoside prodrugs for treating  
Flaviviridae infections  
IN Sommadossi, Jean-pierre; La Colla, Poalo; Storer, Richard; Gosselin,  
Gilles

McIntosh




10/608,907

PA Idenix (Cayman) Limited, Cayman I.; Universita degli studi di Cagliari;  
Centre National de la Recherche Scientifique  
SO PCT Int. Appl., 201 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004002999	A2	20040108	WO 2003-IB3246	20030627
	WO 2004002999	A3	20040812		
	WO 2004002999	A8	20050217		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2490191	A1	20040108	CA 2003-2490191	20030627
	AU 2003247084	A1	20040119	AU 2003-247084	20030627
	EP 1523489	A2	20050420	EP 2003-761744	20030627
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	CN 1678621	A	20051005	CN 2003-820690	20030627
	JP 2005533817	T	20051110	JP 2004-517158	20030627
	CN 1761677	A	20060419	CN 2003-820501	20030627
	US 2007087960	A1	20070419	US 2003-608907	20030627 <--
	WO 2005020884	A2	20050310	WO 2004-US15395	20040514
	WO 2005020884	A3	20060622		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1656093	A2	20060517	EP 2004-776022	20040514
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
	US 2007027065	A1	20070201	US 2004-5468	20041206
	US 2007027104	A1	20070201	US 2004-5469	20041206
	US 2007027066	A1	20070201	US 2004-5470	20041206
	US 2007032449	A1	20070208	US 2004-5441	20041206
	US 2007032407	A1	20070208	US 2004-5473	20041206
	US 7192936	B2	20070320		
	US 2007037735	A1	20070215	US 2004-5442	20041206
	US 2007042939	A1	20070222	US 2004-5445	20041206
	US 2007042991	A1	20070222	US 2004-5447	20041206
	US 2007042940	A1	20070222	US 2004-5467	20041206
	US 2007042990	A1	20070222	US 2004-5471	20041206
	US 2007060503	A1	20070315	US 2004-5440	20041206
	US 2007060498	A1	20070315	US 2004-5444	20041206
	US 2007060504	A1	20070315	US 2004-5446	20041206
	US 2007060541	A1	20070315	US 2004-5466	20041206
	US 2007060505	A1	20070315	US 2004-5472	20041206
	NO 2005000465	A	20050127	NO 2005-465	20050127
PRAI	US 2002-392350P	P	20020628		
	US 2002-392351P	P	20020628		
	US 2003-466194P	P	20030428		
	US 2003-470949P	P	20030514		
	US 2003-608907	A1	20030627		
	US 2003-609298	A1	20030627		
	WO 2003-IB3246	W	20030627		
	WO 2004-US15395	W	20040514		
OS	MARPAT 140:77365				
GI					


McIntosh



I

- AB 2' And/or 3' prodrugs of 1', 2', 3' or 4'-branched-nucleosides I, wherein R1-R3 are independently H, phosphate, alkyl, acyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, sulfonate ester, benzyl, wherein the Ph group is optionally substituted with one or more substituents, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, lipid, amino acid, carbohydrate, peptide, cholesterol; Y1 is hydrogen, bromo, chloro, fluoro, iodo, CN, OH, OR4, NH2, NHR4, NR4R5, SH or SR4; X1 and X2 are independently alkyl, CH3, CF3, CY3, 2-Br-Et, CH2F, CH2Cl, CH2CF3, CF2CF3, CY2CY3, CH2OH, alkenyl, alkynyl, COOH, COOR4, COO-alkyl, COO-aryl, CO-O-alkoxyalkyl, CONH2, CONHR4, CON(R4)2, halo, CN, N3, OH, OR4, NH2, NHR4, NR4R5, SH or SR5; Y is independently H, halo; and each R4 and R5 is independently hydrogen, acyl, alkyl, lower alkyl, alkenyl, alkynyl or cycloalkyl, and their pharmaceutically acceptable salts and derivs. are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compds. and compns. of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivs. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions. Thus, antiviral activity of  $\beta$ -D-2'-C-methyl-7-methyl-6-phenyl-3,3a,5,8a-tetrahydro-1,3,4,5,7a-penta-aza-s-indacen-8-one is reported.
- IT 4099-85-8P 33985-40-9P 55797-67-6P  
327614-68-6P 327614-69-7P 503543-43-9P  
503543-44-0P 640281-90-9P  
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of modified and nucleoside prodrugs for treating flaviviridae infections)
- RN 4099-85-8 CAPLUS
- CN  $\beta$ -D-Ribofuranoside, methyl 2,3-O-(1-methylethylidene)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



- RN 33985-40-9 CAPLUS
- CN  $\beta$ -D-ribo-Pentodialdo-1,4-furanoside, methyl 2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/608,907



RN 55797-67-6 CAPLUS

CN  $\beta$ -D-erythro-Pentofuranoside, methyl 4-C-(hydroxymethyl)-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 327614-68-6 CAPLUS

CN  $\alpha$ -L-Lyxofuranoside, methyl 5-O-[bis(4-methoxyphenyl)phenylmethyl]-4-C-(hydroxymethyl)-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 327614-69-7 CAPLUS

CN  $\alpha$ -L-Lyxofuranoside, methyl 4-C-[(benzoyloxy)methyl]-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 503543-43-9 CAPLUS

CN  $\beta$ -D-Ribofuranoside, methyl 4-C-methyl-2,3-O-(1-methylethylidene)-, benzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/608,907



RN 503543-44-0 CAPLUS

CN D-Ribofuranose, 4-C-methyl-, 1,2,3-triacetate 5-benzoate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 640281-90-9 CAPLUS

CN L-Valine, 3'-ester with 2'-C-methylcytidine (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 640281-91-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL


(Biological study); USES (Uses)

(preparation of modified and nucleoside prodrugs for treating flaviviridae infections)

RN 640281-91-0 CAPLUS

CN 9H-Imidazo[1,2-a]purin-9-one, 3,4-dihydro-7-methyl-3-(2-C-methyl-β-D-ribofuranosyl)-6-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 50-69-1, D-Ribose 13734-41-3 20724-73-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of modified and nucleoside prodrugs for treating flaviviridae infections)


RN 50-69-1 CAPLUS

CN D-Ribose (CA INDEX NAME)

McIntosh

10/608,907


Absolute stereochemistry.



RN 13734-41-3 CAPLUS

CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).





RN 20724-73-6 CAPLUS

CN Cytidine, 2'-C-methyl- (CA INDEX NAME)

Absolute stereochemistry.





chain nodes :

7 8 9 10 11 12 14 15

ring nodes :

1 2 3 4 5 6

chain bonds :

1-7 1-11 2-8 2-10 4-6 4-14 5-12 5-15 8-9

ring bonds :

1-2 1-5 2-3 3-4 4-5

exact/norm bonds :

1-2 1-5 1-7 2-3 3-4 4-5 4-6 5-12

exact bonds :

1-11 2-8 2-10 4-14 5-15 8-9

G1:H,F

G2:CF3,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:CLASS9:CLASS10:CLASS11:CLASS12:CLASS14:CLASS15:CLASS

10/608,907

(FILE 'HOME' ENTERED AT 14:11:26 ON 20 MAY 2007)

FILE 'REGISTRY' ENTERED AT 14:11:53 ON 20 MAY 2007

L1 STRUCTURE UPLOADED

L2 3 S L1 SSS SAM

L3 150 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:13:03 ON 20 MAY 2007

L4 12 S L3

10/608,907

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal600txm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals  
NEWS 3 JAN 16 CA/CAPLUS Company Name Thesaurus enhanced and reloaded  
NEWS 4 JAN 16 IPC version 2007.01 thesaurus available on STN  
NEWS 5 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data  
NEWS 6 JAN 22 CA/CAPLUS updated with revised CAS roles  
NEWS 7 JAN 22 CA/CAPLUS enhanced with patent applications from India  
NEWS 8 JAN 29 PHAR reloaded with new search and display fields  
NEWS 9 JAN 29 CAS Registry Number crossover limit increased to 300,000 in multiple databases  
NEWS 10 FEB 15 PATDPASPC enhanced with Drug Approval numbers  
NEWS 11 FEB 15 RUSSIAPAT enhanced with pre-1994 records  
NEWS 12 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality  
NEWS 13 FEB 26 MEDLINE reloaded with enhancements  
NEWS 14 FEB 26 EMBASE enhanced with Clinical Trial Number field  
NEWS 15 FEB 26 TOXCENTER enhanced with reloaded MEDLINE  
NEWS 16 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements  
NEWS 17 FEB 26 CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases  
NEWS 18 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format  
NEWS 19 MAR 16 CASREACT coverage extended  
NEWS 20 MAR 20 MARPAT now updated daily  
NEWS 21 MAR 22 LWPI reloaded  
NEWS 22 MAR 30 RDISCLOSURE reloaded with enhancements  
NEWS 23 APR 02 JICST-EPLUS removed from database clusters and STN  
NEWS 24 APR 30 GENBANK reloaded and enhanced with Genome Project ID field  
NEWS 25 APR 30 CHEMCATS enhanced with 1.2 million new records  
NEWS 26 APR 30 CA/CAPLUS enhanced with 1870-1889 U.S. patent records  
NEWS 27 APR 30 INPADOC replaced by INPADOCDB on STN  
NEWS 28 MAY 01 New CAS web site launched  
NEWS 29 MAY 08 CA/CAPLUS Indian patent publication number format defined  
NEWS 30 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields  
NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:11:26 ON 20 MAY 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

McIntosh



FILE 'REGISTRY' ENTERED AT 14:11:53 ON 20 MAY 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT'.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)


```
STRUCTURE FILE UPDATES: 18 MAY 2007 HIGHEST RN 935394-90-4
DICTIONARY FILE UPDATES: 18 MAY 2007 HIGHEST RN 935394-90-4
```

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

```
=>
Uploading C:\Program Files\Stnexp\Queries\10608907a.str
```

```
=> d l1
L1 HAS NO ANSWERS
L1 STR
```



Structure attributes must be viewed using STN Express query preparation.

```

20.9% PROCESSED      2000 ITERATIONS                      3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

```


L2 3 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

McIntosh

10/608,907

IN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, phenylmethyl ester, 5'-ester  
with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-  
ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI)  
MF C30 H31 F N5 O7 P

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L2 3 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 9H-Purin-2-amine, 6-chloro-9-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-  
erythro-pentofuranosyl]- (9CI)  
MF C11 H13 Cl F N5 O3


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 3 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Acetamide, N-[7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-  
pentofuranosyl]-5-ethenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI)  
MF C16 H19 Cl N4 O4

Absolute stereochemistry.



McIntosh

10/608,907

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 full

FULL SEARCH INITIATED 14:12:48 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 194430 TO ITERATE

100.0% PROCESSED 194430 ITERATIONS

150 ANSWERS

SEARCH TIME: 00.00.04

L3 150 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.55

172.76

FILE 'CAPLUS' ENTERED AT 14:13:03 ON 20 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 May 2007 VOL 146 ISS 22

FILE LAST UPDATED: 18 May 2007 (20070518/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 12 L3

=> d bib abs hitstr 1-12 l4

L4 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2007:147988 CAPLUS

DN 146:397251

TI Mechanism of activation of  $\beta$ -D-2'-deoxy-2'-fluoro-2'-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase

AU Murakami, Eisuke; Bao, Haiying; Ramesh, Mangala; McBrayer, Tamara R.; Whitaker, Tony; Steuer, Holly M. Micolochick; Schinazi, Raymond F.; Stuyver, Lieven J.; Obikhod, Aleksandr; Otto, Michael J.; Furman, Phillip A.

CS Pharmasset, Inc., Princeton, NJ, 08540, USA

SO Antimicrobial Agents and Chemotherapy (2007), 51(2), 503-509

CODEN: AMACQ; ISSN: 0066-4804

PB American Society for Microbiology

DT Journal

LA English


AB  $\beta$ -D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) is a potent specific inhibitor of hepatitis C virus (HCV) RNA synthesis in Huh-7 replicon cells. To inhibit the HCV NS5B RNA polymerase, PSI-6130 must be phosphorylated to the 5'-triphosphate form. The phosphorylation of PSI-6130 and inhibition of HCV NS5B were investigated. The phosphorylation of PSI-6130 by recombinant human 2'-deoxycytidine kinase (dCK) and uridine-cytidine kinase 1 (UCK-1) was measured by using a coupled spectrophotometric reaction. PSI-6130 was shown to be a substrate for purified dCK, with a  $K_m$  of 81  $\mu$ M and a  $k_{cat}$  of 0.007 s<sup>-1</sup>, but was not a substrate for UCK-1. PSI-6130 monophosphate (PSI-6130-MP) was

McIntosh

efficiently phosphorylated to the diphosphate and subsequently to the triphosphate by recombinant human UMP-CMP kinase and nucleoside diphosphate kinase, resp. The inhibition of wild-type and mutated (S282T) HCV NS5B RNA polymerases was studied. The steady-state inhibition constant ( $K_i$ ) for PSI-6130 triphosphate (PSI-6130-TP) with the wild-type enzyme was 4.3  $\mu\text{M}$ . Similar results were obtained with 2'-C-methyladenosine triphosphate ( $K_i = 1.5 \mu\text{M}$ ) and 2'-C-methylcytidine triphosphate ( $K_i = 1.6 \mu\text{M}$ ). NS5B with the S282T mutation, which is known to confer resistance to 2'-C-methyladenosine, was inhibited by PSI-6130-TP as efficiently as the wild-type. Incorporation of PSI-6130-MP into RNA catalyzed by purified NS5B RNA polymerase resulted in chain termination.


IT 817204-44-7, PSI 6130 triphosphate 932721-63-6, PSI 6130 monophosphate 932721-64-7, PSI 6130 diphosphate  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (formation; mechanism of activation of  $\beta$ -D-2'-deoxy-2'-fluoro-2'-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase)  
 RN 817204-44-7 CAPLUS  
 CN Cytidine 5'-(tetrahydrogen triphosphate), 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 932721-63-6 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 932721-64-7 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



IT 817204-33-4, PSI 6130  
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (mechanism of activation of  $\beta$ -D-2'-deoxy-2'-fluoro-2'-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase)  
 RN 817204-33-4 CAPLUS  
 CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:1158278 CAPLUS  
DN 145:489507  
TI Preparation of fluorinated nucleosides for treating hepatitis C  
IN Chang, Junbiao; Yu, Xuejun; Bao, Xinhong; Ye, Zhaoting  
PA Henan Kaite Chemical Industry General Corporation, Peop. Rep. China  
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 12pp.  
CODEN: CNXXEV  
DT Patent  
LA Chinese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1712409	A	20051228	CN 2005-10017709	20050620
PRAI	CN 2005-10017709		20050620		
OS	CASREACT 145:489507				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title fluorinated nucleosides I and II [wherein R1 = H, Me, CN, N3, etc.; R2 = H, NH2, OMe, F, Cl, etc.; R3 = H, NH2, F, Cl, etc.; R4 = F, Cl, Br, CN, N3, etc.], or prodrugs or salts thereof were prepared for the treatment of hepatitis C (no data). For example, I [wherein R1 and R3 = H; R2 = 3-thiophenyl] were prepared in a multi-step synthesis.

IT 892389-10-5P 914377-14-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of fluorinated nucleosides for treating hepatitis C)

RN 892389-10-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 914377-14-3 CAPLUS

CN 9H-Purine, 9-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-6-(3-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/608,907




IT 914377-15-4P 914377-17-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(intermediate; preparation of fluorinated nucleosides for treating hepatitis  
C)  
RN 914377-15-4 CAPLUS  
CN 9H-Purine, 9-[(2R)-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-methyl- $\beta$ -D-  
erythro-pentofuranosyl]-6-(3-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 914377-17-6 CAPLUS  
CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-[(2R)-3,5-di-O-benzoyl-2-deoxy-2-  
fluoro-2-methyl- $\beta$ -D-erythro-pentofuranosyl]-5-fluoro- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



IT 914377-16-5P 914377-18-7P  
RL: BYP (Byproduct); SPN (Synthetic preparation); PREP (Preparation)  
(preparation of fluorinated nucleosides for treating hepatitis C)  
RN 914377-16-5 CAPLUS  
CN 9H-Purine, 9-[(2R)-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-methyl- $\alpha$ -D-  
erythro-pentofuranosyl]-6-(3-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

McIntosh



RN 914377-18-7 CAPLUS  
 CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-[(2R)-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-methyl-α-D-erythro-pentofuranosyl]-5-fluoro- (9CI) (CA)  
 INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:1124279 CAPLUS  
 DN 145:455221  
 TI Preparation of nucleoside analogs for treating Flaviviridae family viral infections  
 IN Roberts, Christopher D.; Griffith, Ronald Conrad; Dyatkina, Natalia B.; Prhavic, Marija  
 PA Genelabs Technologies, Inc., USA  
 SO U.S. Pat. Appl. Publ., 71pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006241064	A1	20061026	US 2006-411434	20060425
WO 2006116557	A1	20061102	WO 2006-US15940	20060425

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2005-674731P P 20050425  
 GI




AB Nucleoside analogs I, wherein Y is O or CH<sub>2</sub>; X is a halo, hydroxy, alkyl group; W is H, alkyl, etc.; R<sub>1</sub> is H, hydroxy, acyl, alkyl, alkoxy; T is an (un)substituted alkynyl group; R<sub>2</sub> is an H, alkyl, or a pharmaceutically active prodrug group are prepared for treating viral infections caused by a Flaviviridae family virus. Thus, II was prepared and exhibited 95% inhibition at 6 μM in an HCV-NS5b enzyme assay. Further, I were tested for their anti-Hepatitis C activity against HCV polymerase, in replication assays, and in the cloning expression of recombinant HCV-NS5b.

IT 913188-79-1P 913188-91-7P 913188-92-8P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of nucleoside analogs for treating Flaviviridae family viral infections)

RN 913188-79-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913188-91-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-[(trimethylsilyl)ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913188-92-8 CAPLUS

CN 2-Propynoic acid, 3-[4-amino-7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, ethyl ester


McIntosh



10/608,907

(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 913188-93-9P 913188-94-0P 913188-95-1P  
913188-96-2P 913188-97-3P 913188-98-4P  
913188-99-5P 913189-00-1P 913189-01-2P  
913189-02-3P 913189-03-4P 913189-04-5P  
913189-05-6P 913189-06-7P 913189-07-8P  
913189-08-9P 913189-09-0P 913189-10-3P  
913189-11-4P 913189-12-5P 913189-13-6P  
913189-14-7P 913189-15-8P 913189-16-9P  
913189-18-1P 913189-19-2P 913189-20-5P  
913189-21-6P 913189-23-8P 913189-24-9P  
913189-25-0P 913189-26-1P 913189-27-2P  
913189-28-3P 913189-29-4P 913189-30-7P  
913189-31-8P 913189-32-9P 913189-33-0P  
913189-34-1P 913189-35-2P 913189-36-3P  
913189-37-4P 913189-38-5P 913189-39-6P  
913189-40-9P 913189-41-0P 913189-42-1P  
913189-43-2P 913189-44-3P 913189-45-4P  
913189-46-5P 913189-47-6P 913189-48-7P  
913189-49-8P 913189-50-1P 913189-51-2P  
913189-52-3P 913189-53-4P 913189-54-5P  
913189-55-6P 913189-56-7P 913189-57-8P  
913189-58-9P 913189-59-0P 913189-60-3P  
913189-61-4P 913189-62-5P 913189-63-6P  
913189-64-7P 913189-65-8P 913189-66-9P  
913189-67-0P 913189-68-1P 913189-69-2P  
913189-70-5P 913189-71-6P 913189-72-7P  
913189-73-8P 913189-74-9P 913189-75-0P  
913189-76-1P 913190-13-3P 913190-14-4P  
913190-15-5P 913190-16-6P 913190-17-7P  
913190-18-8P 913190-19-9P 913190-20-2P  
913190-21-3P 913190-22-4P 913190-23-5P  
913190-24-6P 913190-25-7P 913190-26-8P  
913190-27-9P 913190-28-0P 913190-29-1P  
913190-30-4P 913190-31-5P 913190-32-6P  
913190-33-7P 913190-34-8P 913190-35-9P  
913190-36-0P 913190-37-1P 913190-38-2P  
913190-39-3P 913190-40-6P 913190-41-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of nucleoside analogs for treating Flaviviridae family viral  
infections)

RN 913188-93-9 CAPLUS

CN 2-Propynamide, 3-[4-amino-7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-  
erythro-pentofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.



RN 913188-94-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-deoxy-2-fluoro-5-O-[[[(1S)-2-methoxy-1-methyl-2-oxoethyl]amino]phenoxyphosphinyl]-2-methyl-beta-D-erythro-pentofuranosyl]-5-ethynyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913188-95-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-deoxy-2-fluoro-5-O-[[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-methyl-beta-D-erythro-pentofuranosyl]-5-ethynyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913188-96-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-beta-D-erythro-pentofuranosyl]-5-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913188-97-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-

10/608,907

$\beta$ -D-erythro-pentofuranosyl]-5-(2-phenylethynyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913188-98-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-amino-7-[(2R)-2-deoxy-2-fluoro-2-methyl- $\beta$ -D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913188-99-5 CAPLUS

CN Boronic acid, [4-amino-7-[(2R)-2-deoxy-2-fluoro-2-methyl- $\beta$ -D-erythro-pentofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-00-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-deoxy-2-fluoro-2-methyl- $\beta$ -D-erythro-pentofuranosyl]-5-ethenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/608,907

RN 913189-01-2 CAPLUS

CN Formaldehyde, [4-amino-7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]hydrazone (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913189-02-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-amino-7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 913189-03-4 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-1,7-dihydro-5-nitro-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913189-04-5 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-1,7-dihydro-5-(phenylethynyl)-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/608,907



RN 913189-05-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-4-(hydroxyamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-06-7 CAPLUS

CN Boronic acid, [7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-4-(hydroxyamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-07-8 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-1,7-dihydro-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/608,907

RN 913189-08-9 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-1,7-dihydro-5-[(trimethylsilyl)ethynyl]-, oxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-09-0 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethenyl-1,7-dihydro-, oxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-10-3 CAPLUS

CN Formaldehyde, [7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-4-(hydroxyamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]hydrazone (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913189-11-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-4-(hydroxyamino)-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.


10/608,907



RN 913189-12-5 CAPLUS

CN Acetamide, N-[7-((2R)-2-deoxy-2-fluoro-2-methyl-beta-D-erythro-pentofuranosyl)-5-nitro-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-13-6 CAPLUS

CN Acetamide, N-[7-((2R)-2-deoxy-2-fluoro-2-methyl-beta-D-erythro-pentofuranosyl)-5-(phenylethynyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-14-7 CAPLUS

CN Acetamide, N-[7-((2R)-2-deoxy-2-fluoro-2-methyl-beta-D-erythro-pentofuranosyl)-5-formyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913189-15-8 CAPLUS

McIntosh

10/608,907

CN Boronic acid, [4-(acetamino)-7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-16-9 CAPLUS

CN Acetamide, N-[7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-18-1 CAPLUS

CN Acetamide, N-[7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-[2-(trimethylsilyl)ethynyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913189-19-2 CAPLUS

CN Acetamide, N-[7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/608,907



RN 913189-20-5 CAPLUS

CN Acetamide, N-[7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-(methylenedihydropyrimidin-4-yl)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913189-21-6 CAPLUS

CN Acetamide, N-[7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-[(hydroxyimino)methyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 913189-23-8 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-1,7-dihydro-5-nitro-, O-ethyloxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/608,907



RN 913189-24-9 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-beta-D-erythro-pentofuranosyl]-1,7-dihydro-5-(phenylethynyl)-, O-ethyloxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-25-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-beta-D-erythro-pentofuranosyl]-4-(ethoxyamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-26-1 CAPLUS

CN Boronic acid, [7-[(2R)-2-deoxy-2-fluoro-2-methyl-beta-D-erythro-pentofuranosyl]-4-(ethoxyamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/608,907

RN 913189-27-2 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-1,7-dihydro-, O-ethyloxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-28-3 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-1,7-dihydro-5-[2-(trimethylsilyl)ethynyl]-, O-ethyloxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-29-4 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethenyl-1,7-dihydro-, O-ethyloxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913189-30-7 CAPLUS

CN Formaldehyde, [7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-4-(ethoxyamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]hydrazone (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/608,907



RN 913189-31-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 7-[(2R)-2-deoxy-2-fluoro-2-methyl- $\beta$ -D-erythro-pentofuranosyl]-4-(ethoxyamino)-, oxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 913189-32-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-chloro-2-deoxy-2-methyl- $\beta$ -D-erythro-pentofuranosyl]-5-nitro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-33-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-chloro-2-deoxy-2-methyl- $\beta$ -D-erythro-pentofuranosyl]-5-(phenylethynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913189-34-1 CAPLUS

McIntosh

10/608,907

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-amino-7-[(2R)-2-chloro-2-deoxy-2-methyl- $\beta$ -D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-35-2 CAPLUS

CN Boronic acid, [4-amino-7-[(2R)-2-chloro-2-deoxy-2-methyl- $\beta$ -D-erythro-pentofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-36-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-chloro-2-deoxy-2-methyl- $\beta$ -D-erythro-pentofuranosyl]-5-ethynyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-37-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-chloro-2-deoxy-2-methyl- $\beta$ -D-erythro-pentofuranosyl]-5-[2-(trimethylsilyl)ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/608,907

RN 913189-38-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-chloro-2-deoxy-2-methyl- $\beta$ -D-erythro-pentofuranosyl]-5-ethenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-39-6 CAPLUS

CN Formaldehyde, [4-amino-7-[(2R)-2-chloro-2-deoxy-2-methyl- $\beta$ -D-erythro-pentofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]hydrazone (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913189-40-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-amino-7-[(2R)-2-chloro-2-deoxy-2-methyl- $\beta$ -D-erythro-pentofuranosyl]-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 913189-41-0 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-chloro-2-deoxy-2-methyl- $\beta$ -D-erythro-pentofuranosyl]-1,7-dihydro-5-nitro-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/608,907



RN 913189-42-1 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-chloro-2-deoxy-2-methyl-beta-D-erythro-pentofuranosyl]-1,7-dihydro-5-(phenylethynyl)-, oxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-43-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 7-[(2R)-2-chloro-2-deoxy-2-methyl-beta-D-erythro-pentofuranosyl]-4-(hydroxyamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-44-3 CAPLUS

CN Boronic acid, [7-[(2R)-2-chloro-2-deoxy-2-methyl-beta-D-erythro-pentofuranosyl]-4-(hydroxyamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/608,907

RN 913189-45-4 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-1,7-dihydro-, oxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-46-5 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-1,7-dihydro-5-[(trimethylsilyl)ethynyl]-, oxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-47-6 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-ethenyl-1,7-dihydro-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913189-48-7 CAPLUS

CN Formaldehyde, [7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-4-(hydroxyamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]hydrazone (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/608,907



RN 913189-49-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-4-(hydroxyamino)-, oxime (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 913189-50-1 CAPLUS

CN Acetamide, N-[7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-nitro-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-51-2 CAPLUS

CN Acetamide, N-[7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-(phenylethynyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/608,907

RN 913189-52-3 CAPLUS

CN Acetamide, N-[7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-formyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-53-4 CAPLUS

CN Boronic acid, [4-(acetamino)-7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-54-5 CAPLUS

CN Acetamide, N-[7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913189-55-6 CAPLUS

CN Acetamide, N-[7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-[(trimethylsilyl)ethynyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/608,907



RN 913189-56-7 CAPLUS

CN Acetamide, N-[7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-57-8 CAPLUS

CN Acetamide, N-[7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-(methylenedihydro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913189-58-9 CAPLUS

CN Acetamide, N-[7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-[(hydroxyimino)methyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




McIntosh

10/608,907

RN 913189-59-0 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-1,7-dihydro-5-nitro-, O-ethyloxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-60-3 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-1,7-dihydro-5-(phenylethynyl)-, O-ethyloxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-61-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-4-(ethoxyamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913189-62-5 CAPLUS

CN Boronic acid, [7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-4-(ethoxyamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/608,907



RN 913189-63-6 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-1,7-dihydro-, O-ethyloxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-64-7 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-1,7-dihydro-5-[(trimethylsilyl)ethynyl]-, O-ethyloxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-65-8 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-ethenyl-1,7-dihydro-, O-ethyloxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/608,907

RN 913189-66-9 CAPLUS  
CN Formaldehyde, [7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-4-(ethoxyamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]hydrazone (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-67-0 CAPLUS  
CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-4-(ethoxyamino)-, oxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.



RN 913189-68-1 CAPLUS  
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-bromo-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-nitro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-69-2 CAPLUS  
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-bromo-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-(phenylethynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/608,907



RN 913189-70-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-amino-7-[(2R)-2-bromo-2-deoxy-2-methyl- $\beta$ -D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-71-6 CAPLUS

CN Boronic acid, [4-amino-7-[(2R)-2-bromo-2-deoxy-2-methyl- $\beta$ -D-erythro-pentofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-72-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-bromo-2-deoxy-2-methyl- $\beta$ -D-erythro-pentofuranosyl]-5-ethynyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913189-73-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-bromo-2-deoxy-2-methyl- $\beta$ -D-erythro-pentofuranosyl]-5-[(trimethylsilyl)ethynyl]- (9CI) (CA INDEX NAME)

McIntosh

10/608,907


Absolute stereochemistry.



RN 913189-74-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-bromo-2-deoxy-2-methyl- $\beta$ -D-erythro-pentofuranosyl]-5-ethynyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913189-75-0 CAPLUS

CN Formaldehyde, [4-amino-7-[(2R)-2-bromo-2-deoxy-2-methyl- $\beta$ -D-erythro-pentofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]hydrazone (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913189-76-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-amino-7-[(2R)-2-bromo-2-deoxy-2-methyl- $\beta$ -D-erythro-pentofuranosyl]-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.






RN 913190-13-3 CAPLUS

CN L-Valine, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913190-14-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-5-O-[bis[2-[(2,2-dimethyl-1-oxopropyl)thio]ethoxy]phosphinyl]-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913190-15-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-5-O-[bis[2-[(3-methyl-1-oxobutyl)thio]ethoxy]phosphinyl]-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913190-16-6 CAPLUS

McIntosh

10/608,907

CN L-Alanine, N-[hydroxy(4-methoxyphenoxy)phosphinyl]-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913190-17-7 CAPLUS

CN L-Alanine, N-[(4-fluorophenoxy)hydroxyphosphinyl]-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913190-18-8 CAPLUS

CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, ethyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913190-19-9 CAPLUS

CN L-Alanine, N-[hydroxy(4-methylphenoxy)phosphinyl]-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913190-20-2 CAPLUS

CN L-Alanine, N-[hydroxy(4-propylphenoxy)phosphinyl]-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913190-21-3 CAPLUS

CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, phenylmethyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913190-22-4 CAPLUS

CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, phenylmethyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/608,907

RN 913190-23-5 CAPLUS

CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, phenylmethyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913190-24-6 CAPLUS

CN L-Alanine, N-[[[(4-chloro-1-naphthalenyl)oxy]hydroxyphosphinyl]-, phenylmethyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913190-25-7 CAPLUS

CN L-Alanine, N-[hydroxy[(4-methoxy-1-naphthalenyl)oxy]phosphinyl]-, phenylmethyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-26-8 CAPLUS


CN L-Phenylalanine, N-(hydroxyphenoxyphosphinyl)-, methyl ester, 5'-ester

McIntosh

10/608,907

with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913190-27-9 CAPLUS

CN L-Phenylalanine, N-[hydroxy(4-methoxyphenoxy)phosphinyl]-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913190-28-0 CAPLUS

CN L-Phenylalanine, N-[(4-fluorophenoxy)hydroxyphosphinyl]-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913190-29-1 CAPLUS

CN L-Phenylalanine, N-[hydroxy(4-methylphenoxy)phosphinyl]-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913190-30-4 CAPLUS

CN L-Valine, N-(hydroxyphenoxyphosphinyl)-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913190-31-5 CAPLUS

CN L-Valine, N-[hydroxy(4-methoxyphenoxy)phosphinyl]-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913190-32-6 CAPLUS

CN L-Valine, N-[(4-fluorophenoxy)hydroxyphosphinyl]-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/608,907

RN 913190-33-7 CAPLUS

CN L-Valine, N-[hydroxy(4-methylphenoxy)phosphinyl]-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913190-34-8 CAPLUS

CN Alanine, N-(hydroxyphenoxyphosphinyl)-2-methyl-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913190-35-9 CAPLUS

CN Alanine, N-(hydroxyphenoxyphosphinyl)-2-methyl-, phenylmethyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913190-36-0 CAPLUS

CN Alanine, N-[(4-fluorophenoxy)hydroxyphosphinyl]-2-methyl-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913190-37-1 CAPLUS

CN Alanine, N-[hydroxy(4-methoxyphenoxy)phosphinyl]-2-methyl-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913190-38-2 CAPLUS

CN L-Proline, 1-(hydroxyphenoxyphosphinyl)-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913190-39-3 CAPLUS

CN L-Proline, 1-(hydroxyphenoxyphosphinyl)-, phenylmethyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.






10/608,907

RN 913190-40-6 CAPLUS

CN L-Proline, 1-[(4-fluorophenoxy)hydroxyphosphinyl]-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913190-41-7 CAPLUS

CN L-Proline, 1-[hydroxy(4-methoxyphenoxy)phosphinyl]-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (CA INDEX NAME)

Absolute stereochemistry.




IT 913188-88-2P 913188-89-3P 913188-90-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of nucleoside analogs for treating Flaviviridae family viral infections)

RN 913188-88-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-[(2R)-2-deoxy-2-fluoro-2-methyl-3,5-bis-O-(tetrahydro-2H-pyran-2-yl)-β-D-erythro-pentofuranosyl]-5-iodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913188-89-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-iodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


McIntosh

10/608,907




RN 913188-90-6 CAPLUS  
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-  
β-D-erythro-pentofuranosyl]-5-iodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:985303 CAPLUS  
DN 145:505687  
TI Synthesis of 2-deoxy-2-fluoro-2-C-methyl-D-ribofuranoses  
AU Clark, Jeremy L.; Mason, J. Christian; Hobbs, Ann J.; Hollecker, Laurent;  
Schinazi, Raymond F.  
CS Pharmasset, Inc., Tucker, GA, USA  
SO Journal of Carbohydrate Chemistry (2006), 25(6), 461-470  
CODEN: JCACDM; ISSN: 0732-8303  
PB Taylor & Francis, Inc.  
DT Journal  
LA English  
OS CASREACT 145:505687  
AB The synthesis of Me 3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-C-methyl-β-D-  
ribofuranoside and the conversion to the corresponding  
1-O-acetyl-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-C-methyl-D-ribofuranose and  
1,3,5-tri-O-benzoyl-2-deoxy-2-fluoro-2-C-methyl-D-ribofuranose is  
reported. The key synthetic step is the fluorination of the tertiary  
center of Me 3,5-di-O-benzyl-2-C-methyl-β-D-arabinofuranoside to  
provide Me 3,5-di-O-benzyl-2-deoxy-2-fluoro-2-C-methyl-β-D-  
ribofuranoside.  
IT 817204-32-3P 874638-94-5P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(synthesis of 2-deoxy-2-fluoro-2-C-methyl-D-ribofuranoses via  
fluorination of the tertiary center of Me 3,5-di-O-benzyl-2-C-methyl-  
β-D-arabinofuranosides)  
RN 817204-32-3 CAPLUS  
CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoate,  
(2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 874638-94-5 CAPLUS  
 CN Benzamide, N-[1-((2R)-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-methyl- $\alpha$ -D-erythro-pentofuranosyl)-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:603846 CAPLUS  
 DN 145:76603  
 TI Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection  
 IN Maccoss, Malcolm; Olsen, David B.; Leone, Joseph; Durette, Philippe L.  
 PA Merck & Co., Inc., USA  
 SO PCT Int. Appl., 46 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006065335	A2	20060622	WO 2005-US37224	20051017
WO 2006065335	A3	20060914		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI US 2004-620743P	P	20041021		
US 2005-651366P	P	20050209		
OS MARPAT 145:76603				

AB The present invention provides fluorinated pyrrolo[2,3, d]pyrimidine nucleoside compds. which are inhibitors of RNA-dependent RNA viral polymerase. These compds. are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of

HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compns. containing such fluorinated pyrrolo[2,3- d]pyrimidine nucleoside alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the fluorinated pyrrolo[2,3- d]pyrimidine nucleoside of the present invention.


IT 892389-29-6 892389-31-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(fluorinated pyrrolopyrimidine nucleosides for treatment of RNA-dependent RNA viral infection)

RN 892389-29-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 892389-31-0 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-fluoro-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 892389-27-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(fluorinated pyrrolopyrimidine nucleosides for treatment of RNA-dependent RNA viral infection)

RN 892389-27-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-[(2R)-3,5-di-O-acetyl-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/608,907


IT 892389-10-5P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(fluorinated pyrrolopyrimidine nucleosides for treatment of  
RNA-dependent RNA viral infection)  
RN 892389-10-5 CAPLUS  
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-  
β-D-erythro-pentofuranosyl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:478128 CAPLUS  
DN 145:202057  
TI Inhibition of hepatitis C replicon RNA synthesis by β-D-2'-deoxy-2'-  
fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus  
replication  
AU Stuyver, Lieven J.; McBrayer, Tamara R.; Tharnish, Phillip M.; Clark,  
Jeremy; Hollecker, Laurent; Lostia, Stefania; Nachman, Tammy; Grier,  
Jason; Bennett, Matthew A.; Xie, Meng-Yu; Schinazi, Raymond F.; Morrey,  
John D.; Julander, Justin L.; Furman, Phillip A.; Otto, Michael J.  
CS Pharmasset Inc, Princeton, NJ, USA  
SO Antiviral Chemistry & Chemotherapy (2006), 17(2), 79-87  
CODEN: ACCHEH; ISSN: 0956-3202  
PB International Medical Press, Ltd.  
DT Journal  
LA English  
AB β-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) is a cytidine  
analog with potent and selective anti-hepatitis C virus (HCV) activity in  
the subgenomic HCV replicon assay, 90% effective concentration (EC90) = 4.6 ±  
2.0 μM. The spectrum of activity and cytotoxicity profile of PSI-6130  
was evaluated against a diverse panel of viruses and cell types, and  
against two addnl. HCV-1b replicons. The S282T mutation, which confers  
resistance to 2'-C-Me adenosine and other 2'-methylated nucleosides,  
showed only a 6.5-fold increase in EC90. When assayed for activity  
against bovine diarrhoea virus (BVDV), which is typically used as a  
surrogate assay to identify compds. active against HCV, PSI-6130 showed no  
anti-BVDV activity. Weak antiviral activity was noted against other  
flaviviruses, including West Nile virus, Dengue type 2, and yellow fever  
virus. These results indicate that PSI-6130 is a specific inhibitor of  
HCV. PSI-6130 showed little or no cytotoxicity against various cell  
types, including human peripheral blood mononuclear and human bone marrow  
progenitor cells. No mitochondrial toxicity was observed with PSI-6130. The  
reduced activity against the RdRp S282T mutant suggests that PSI-6130 is  
an inhibitor of replicon RNA synthesis. Finally, the no-effect dose for  
mice treated i.p. with PSI-6130 for six consecutive days was ≥100  
mg/kg per day.  
IT 817204-33-4, PSI 6130  
RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of  
action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(PSI-6130 inhibition of hepatitis C replicon RNA synthesis)  
RN 817204-33-4 CAPLUS  
CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:269477 CAPLUS  
DN 144:312289  
TI Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl  
pyrimidine and purine nucleoside analogs via condensation of the lactone  
to nucleosides as potential antiviral agents  
IN Chun, Byoung-Kwon, Wang, Pelyuan  
PA Pharmasset, Inc., USA  
SO PCT Int. Appl., 74 pp.  
CODEN: PRXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006031725	A2	20060323	WO 2005-US32406	20050913
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 2006122146	A1	20060608	US 2005-225425	20050913
PRAI US 2004-609783P	P	20040914		
US 2004-610035P	P	20040915		
US 2005-666230P	P	20050329		
OS MARPAT 144:312289				
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB A process for preparing of 2-deoxy-2-fluoro-2-methyl-D-ribonolactones, I, wherein R1 and R2 can independently be H, CH3, acetyl, benzoyl, pivaloyl, 4-nitrobenzoyl, 3-nitrobenzoyl, 2-nitrobenzoyl, 4-chlorobenzoyl, 3-chlorobenzoyl, 2-chlorobenzoyl, 4-methylbenzoyl, 3-methylbenzoyl, 2-methylbenzoyl, 4-phenylbenzoyl, benzyl, 4-methoxybenzyl, trityl, trialkylsilyl, t-butyl-dialkylsilyl, t-butyldiphenylsilyl, TIPDS, THP, MOM, or MEM are prepared and used in the condensation to 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs. Thus, 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs II and III, wherein X is a halogen; Y is N or CH; Z is a halogen, hydroxyl, ether, thiol, thioether, (un)substituted amine or alkyl; R1' is alkyl, vinyl, ethynyl; R2' and R3' can be same or different H, alkyl, arylalkyl, acyl, cyclic acetal such as 2',3'-O-isopropylidene or 2',3'-O-benzylidene, or 2',3'-cyclic carbonate; R4, R5, and R6 are independently H, halogen, hydroxyl, ether, thiol, thioether, N3, (un)substituted amine, (un)substituted amido, alkyl, halogenated alkyl, alkenyl, halogenated alkenyl, alkynyl, halogenated alkynyl, hydroxy alkyl, alkoxy are prepared and are potential anti-HCV agents. Specifically, IV was prepared in 88 % yield via condensation, alkylation and stereoselective fluorination reactions and can exhibit potential use as an anti-HCV agent.  
IT 879551-07-2P


10/608,907

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)  
(preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs via condensation of the lactone to nucleosides)

RN 879551-07-2 CAPLUS

CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-bis(2,2-dimethylpropanoate), (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:128527 CAPLUS

DN 144:370341

TI Synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication

AU Clark, Jeremy L.; Mason, J. Christian; Hollecker, Laurent; Stuyver, Lieven J.; Tharnish, Phillip M.; McBrayer, Tamara R.; Otto, Michael J.; Furman, Phillip A.; Schinazi, Raymond F.; Watanabe, Kyoichi A.

CS Pharmasset, Inc., Tucker, GA, 30084, USA

SO Bioorganic & Medicinal Chemistry Letters (2006) 16(6), 1712-1715

CODEN: BMCLE8; ISSN: 0960-894X


PB Elsevier B.V.

DT Journal

LA English

OS CASREACT 144:370341

GI



AB A series of purine nucleosides, e.g. I, containing the 2'-deoxy-2'-fluoro-2'-C-methylribofuranosyl moiety were synthesized and evaluated as potential inhibitors of the hepatitis C virus in vitro. Of the nucleosides that were synthesized, only those possessing a 2-amino group on the purine base reduced the levels of HCV RNA in a sub-genomic replicon assay.

IT 881881-89-6P

RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT'(Reactant or reagent)

(synthesis and antiviral activity of deoxyfluoromethyl purine nucleosides as inhibitors of hepatitis C virus RNA replication)


RN 881881-89-6 CAPLUS

CN 9H-Purin-2-amine, 6-chloro-9-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

McIntosh


10/608,907

Absolute stereochemistry.




IT 817204-42-5P 817204-45-8P 818374-78-6P  
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);  
BIOL (Biological study); PREP (Preparation)  
(synthesis and antiviral activity of deoxyfluoromethyl purine  
nucleosides as inhibitors of hepatitis C virus RNA replication)  
RN 817204-42-5 CAPLUS  
CN 9H-Purine, 6-chloro-9-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-  
pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 817204-45-8 CAPLUS  
CN Guanosine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 818374-78-6 CAPLUS  
CN Adenosine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh



10/608,907


IT 817204-41-4P 881881-83-0P 881881-88-5P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(synthesis and antiviral activity of deoxyfluoromethyl purine  
nucleosides as inhibitors of hepatitis C virus RNA replication)  
RN 817204-41-4 CAPLUS  
CN 9H-Purine, 6-chloro-9-[(2R)-3,5-di-O-acetyl-2-deoxy-2-fluoro-2-methyl-  
β-D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 881881-83-0 CAPLUS  
CN 9H-Purin-2-amine, 6-chloro-9-[(2R)-3,5-di-O-acetyl-2-deoxy-2-fluoro-2-  
methyl-β-D-erythro-pentofuranosyl]-N-(triphenylmethyl)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.



RN 881881-88-5 CAPLUS  
CN 9H-Purin-2-amine, 6-chloro-9-[(2R)-3,5-di-O-acetyl-2-deoxy-2-fluoro-2-  
methyl-β-D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:103884 CAPLUS  
DN 144:171198  
TI Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl  
pyrimidine and purine nucleoside analogs via condensation of the lactone  
to nucleosides as potential antiviral agents  
IN Wang, Peiyuan; Stec, Wojciech; Clark, Jeremy; Chun, Byoung-Kwon; Shi,  
Junxing; Du, Jinfa  
PA Pharmasset, Inc., USA

McIntosh

10/608,907

SO PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006012440	A2	20060202	WO 2005-US25916	20050721
	WO 2006012440	A3	20060727		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2005267051	A1	20060202	AU 2005-267051	20050721
	CA 2574651	A1	20060202	CA 2005-2574651	20050721
	EP 1773856	A2	20070418	EP 2005-775359	20050721
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
	US 2006199783	A1	20060907	US 2006-353597	20060213
PRAI	US 2004-589866P	P	20040721		
	US 2004-608320P	P	20040909		
	US 2005-185988	A1	20050721		
	WO 2005-US25916	W	20050721		
OS	MARPAT 144:171198				
GI					

11/35 3,597

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB A process for preparing of 2-deoxy-2-fluoro-2-methyl-D-ribonolactones, I, wherein R1 and R2 can independently be H, CH3, acetyl, benzoyl, pivaloyl, 4-nitrobenzoyl, 3-nitrobenzoyl, 2-nitrobenzoyl, 4-chlorobenzoyl, 3-chlorobenzoyl, 2-chlorobenzoyl, 4-methylbenzoyl, 3-methylbenzoyl, 2-methylbenzoyl, 4-phenylbenzoyl, benzyl, 4-methoxybenzyl, trityl, trialkylsilyl, t-butyl-dialkylsilyl, t-butyl-diphenylsilyl, TIPDS, THP, MOM, or MEM are prepared and used in the condensation to 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs. Thus, 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs II and III, wherein X is a halogen; Y is N or CH; Z is a halogen, hydroxyl, ether, thiol, thioether, (un)substituted amine or alkyl; R1' is alkyl, vinyl, ethynyl; R2' and R3' can be same or different H, alkyl, arylalkyl, acyl, cyclic acetal such as 2',3'-O-isopropylidene or 2',3'-O-benzylidene, or 2',3'-cyclic carbonate; R4, R5, and R6 are independently H, halogen, hydroxyl, ether, thiol, thioether, N3, (un)substituted amine, (un)substituted amido, alkyl, halogenated alkyl, alkenyl, halogenated alkenyl, alkynyl, halogenated alkynyl, hydroxy alkyl, alkoxy are prepared and are potential anti-HCV agents. Specifically, IV was prepared (no yield, claimed) via condensation, alkylation and stereoselective fluorination reactions and can exhibit potential use as an anti-HCV agent.

IT 874638-97-8P


RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs via condensation of the lactone to nucleosides)

RN 874638-97-8 CAPLUS

CN Adenosine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoate, (2'R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

McIntosh




IT 817204-32-3P 817204-33-4P 874638-82-1P  
 874638-94-5P 874638-95-6P 874638-98-9P  
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP  
 (Preparation)  
 (preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl  
 pyrimidine and purine nucleoside analogs via condensation of the  
 lactone to nucleosides)  
 RN 817204-32-3 CAPLUS  
 CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoate,  
 (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 817204-33-4 CAPLUS  
 CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 874638-82-1 CAPLUS  
 CN Benzamide, N-[1-[(2R)-5-O-benzoyl-2-deoxy-2-fluoro-2-methyl-3-O-  
 (methylsulfonyl)-β-D-erythro-pentofuranosyl]-1,2-dihydro-2-oxo-4-  
 pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 874638-94-5 CAPLUS  
 CN Benzamide, N-[1-[(2R)-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-methyl-α-D-erythro-pentofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 874638-95-6 CAPLUS  
 CN Adenosine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 874638-98-9 CAPLUS  
 CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:648160 CAPLUS  
 DN 143:248607  
 TI Design, Synthesis, and Antiviral Activity of 2'-Deoxy-2'-fluoro-2'-C-methylcytidine, a Potent Inhibitor of Hepatitis C Virus Replication  
 AU Clark, Jeremy L.; Hollecker, Laurent; Mason, J. Christian; Stuyver, Lieven J.; Tharnish, Phillip M.; Lostia, Stefania; McBrayer, Tamara R.; Schinazi, Raymond F.; Watanabe, Kyoichi A.; Otto, Michael J.; Furman, Phillip A.; Stec, Wojciech J.; Patterson, Steven E.; Pankiewicz, Krzysztof W.  
 CS Pharmasset, Inc., Princeton, NJ, 08540, USA  
 SO Journal of Medicinal Chemistry (2005), 48(17), 5504-5508  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 AB The pyrimidine nucleoside-  $\beta$ -D-2'-deoxy-2'-fluoro-2'-C-methylcytidine (I) was designed as a hepatitis C virus RNA-dependent RNA polymerase (HCV RdRp) inhibitor. The title compound was obtained by a DAST fluorination of N4-benzoyl-1-(2-methyl-3,5-di-O-benzoyl- $\beta$ -D-arabinofuranosyl)cytosine to provide N4-benzoyl-1-(2-fluoro-2-methyl-3,5-di-O-benzoyl- $\beta$ -D-ribofuranosyl)cytosine. The protected 2'-C-methylcytidine was obtained as a byproduct from the DAST fluorination and allowed for the preparation of two biol. active compds. from a common precursor. Compound I and 2'-C-methylcytidine were assayed in a sub-genomic HCV replicon assay system and found to be potent and selective inhibitors of HCV replication. Compd. I shows increased inhibitory activity in the HCV replicon assay compared to 2'-C-methylcytidine and low cellular toxicity.  
 IT ~~817204-33-4P~~  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
 (design, synthesis via fluorination, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of Hepatitis C virus replication)  
 RN 817204-33-4 CAPLUS  
 CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 863329-66-2P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (design, synthesis via fluorination, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of Hepatitis C virus replication)  
 RN 863329-66-2 CAPLUS  
 CN Uridine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 817204-32-3P 863329-65-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

10/608,907


(Reactant or reagent)

(design, synthesis via fluorination, and antiviral activity of  
2'-deoxy-2'-fluoro-2'-C-methyl-cytidine, a potent inhibitor of  
Hepatitis C virus replication)

RN 817204-32-3 CAPLUS

CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoate,  
(2'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 863329-65-1 CAPLUS

CN Uridine, 2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoate, (2'R)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 817204-38-9P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(design, synthesis via fluorination, and antiviral activity of  
2'-deoxy-2'-fluoro-2'-C-methyl-cytidine, a potent inhibitor of  
Hepatitis C virus replication)

RN 817204-38-9 CAPLUS

CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, monohydrochloride, (2'R)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:34765 CAPLUS


DN 142:94074

McIntosh

10/608,907

TI Preparation of modified fluorinated (2'R)-2'-deoxy-2'-fluoro-2'-C-methyl  
nucleoside analogs as antiviral agents  
IN Clark, Jeremy  
PA Pharmasset, Ltd., Barbados  
SO PCT Int. Appl., 228 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005003147	A2	20050113	WO 2004-US12472	20040421
	WO 2005003147	A3	20050303		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004253860	A2	20050113	AU 2004-253860	20040421
	AU 2004253860	A1	20050113		
	CA 2527657	A1	20050113	CA 2004-2527657	20040421
	US 2005009737	A1	20050113	US 2004-828753	20040421
	EP 1633766	A2	20060315	EP 2004-775900	20040421
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR			
	BR 2004010846	A	20060627	BR 2004-10846	20040421
	CN 1816558	A	20060809	CN 2004-80019148	20040421
	JP 2006526629	T	20061124	JP 2006-513231	20040421
	NO 2005006221	A	20051228	NO 2005-6221	20051228
PRAI	US 2003-474368P	P	20030530		
	WO 2004-US12472	W	20040421		
OS	MARPAT 142:94074				
GI					



AB The disclosed invention provides nucleoside analogs I, wherein B is purine and pyrimidine nucleobase; X is O, S, CH<sub>2</sub>, Se, NH, N-alkyl, CHW, C(W)<sub>2</sub>; W is F, Cl, Br, iodo; R1 is H, phosphate, H-phosphonate, acyl, Ph, alkyl, carboxyalkylamino, sulfonate ester, peptide, amino acid, sugar residue; R2 and R2' are independently H, alkyl, alkenyl, alkynyl, vanyl, N<sub>3</sub>, CN, halogen, NO<sub>2</sub>, ester, alkoxy, thioalkyl, sulfoxide, sulfonyl; R6 is alkyl, CN, Me, OMe, OEt, CH<sub>2</sub>OH, CH<sub>2</sub>F, N<sub>3</sub>, CHCN, CH<sub>2</sub>N<sub>3</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NHMe, CH<sub>2</sub>NMe<sub>2</sub>, alkylne; and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially human, using a (2'R)-2'-deoxy-2'-fluoro-2'-C-Me nucleosides, or a pharmaceutically acceptable salt or prodrug thereof. Thus, (2'R)-2'-deoxy-2'-fluoro-2'-C-methylcytidine was prepared and tested as antiviral agent. The effects the nucleoside analogs tested on human bone marrow cells are reported. (2'R)-2'-deoxy-2'-fluoro-2'-C-methylcytidine shows activity against Rhinovirus, West Nile virus, Yellow Fever virus, and Dengue virus. Cytotoxicity and effect of nucleoside analogs on human bone marrow cells are reported.

IT 817204-33-4P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of modified fluorinated (2'R)-2'-deoxy-2'-fluoro-2'-C-Me nucleoside analogs as antiviral agents)


McIntosh

10/608,907

RN 817204-33-4 CAPLUS

CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 817204-38-9P 817204-42-5P 817204-43-6P

817204-45-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of modified fluorinated (2'R)-2'-deoxy-2'-fluoro-2'-C-Me nucleoside analogs as antiviral agents)

RN 817204-38-9 CAPLUS

CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, monohydrochloride, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

RN 817204-42-5 CAPLUS

CN 9H-Purine, 6-chloro-9-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 817204-43-6 CAPLUS


CN Adenosine, 2'-deoxy-2'-fluoro-2'-methyl-, monohydrochloride, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh



10/608,907




● HCl

RN 817204-45-8 CAPLUS

CN Guanosine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 817204-44-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL


(Biological study); USES (Uses)

(preparation of modified fluorinated (2'R)-2'-deoxy-2'-fluoro-2'-C-Me nucleoside analogs as antiviral agents)

RN 817204-44-7 CAPLUS

CN Cytidine 5'-(tetrahydrogen triphosphate), 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 817204-32-3P 817204-37-8P 817204-41-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of modified fluorinated (2'R)-2'-deoxy-2'-fluoro-2'-C-Me nucleoside analogs as antiviral agents)

RN 817204-32-3 CAPLUS


CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoate, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 817204-37-8 CAPLUS  
 CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-bis(trifluoroacetate), (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 817204-41-4 CAPLUS  
 CN 9H-Purine, 6-chloro-9-[(2R)-3,5-di-O-acetyl-2-deoxy-2-fluoro-2-methyl-beta-D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:114368 CAPLUS  
 DN 138:304462  
 TI Synthesis of 2'-C-beta-Fluoromethyluridine  
 AU Dai, Qing; Piccirilli, Joseph A.  
 CS Howard Hughes Medical Institute, Department of Biochemistry & Molecular Biology, Department of Chemistry, The University of Chicago, Chicago, IL, 60637, USA  
 SO Organic Letters (2003), 5(6), 807-810  
 CODEN: ORLEF7; ISSN: 1523-7060  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 138:304462  
 AB 2'-C-beta-Fluoromethyluridine represents both a potentially important biol. agent and a tool for biochem. anal. Here the authors describe the first synthesis of this compound starting from uridine. The key steps include protection of the uracil base with methoxyethoxymethyl (MEM) chloride, conversion to the corresponding 2'-C-alpha-epoxide, and regioselective opening of the oxirane ring with potassium fluoride/hydrogen fluoride. Subsequent acetylation of the 3'- and

10/608,907

5'-hydroxyl groups enables MEM removal using B-bromocatecholborane.  
Deacetylation generates the parent nucleoside, 2'-C- $\beta$ -  
fluoromethyluridine.

IT 510765-38-5P


RL: BYP (Byproduct); PREP (Preparation)

(synthesis of C- $\beta$ -fluoromethyluridine from uridine via uracil  
protection with MEM, epoxidn. and regioselective ring opening)

RN 510765-38-5 CAPLUS

CN Uridine, 2'-deoxy-2'-fluoro-2'-(hydroxymethyl)-3-[(2-methoxyethoxy)methyl]-  
, (2'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:11:26 ON 20 MAY 2007)

FILE 'REGISTRY' ENTERED AT 14:11:53 ON 20 MAY 2007

L1 STRUCTURE UPLOADED

L2 3 S L1 SSS SAM

L3 150 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:13:03 ON 20 MAY 2007

L4 12 S L3